It Seems Haemonetics Corporation (HAE) Will Go Up. Just Reaches 52-Week High

April 23, 2018 - By reb123z

Haemonetics Corporation (NYSE:HAE) Logo

Investors sentiment decreased to 1.11 in Q4 2017. Its down 0.17, from 1.28 in 2017Q3. It fall, as 20 investors sold Haemonetics Corporation shares while 77 reduced holdings. 48 funds opened positions while 60 raised stakes. 50.89 million shares or 3.15% less from 52.55 million shares in 2017Q3 were reported.
Credit Suisse Ag holds 0% or 89,514 shares in its portfolio. Moreover, Menta Ltd Llc has 0.11% invested in Haemonetics Corporation (NYSE:HAE). 21,989 are owned by Bnp Paribas Arbitrage Sa. Principal Financial Group Inc stated it has 430,375 shares. Convergence Investment Prtn owns 35,140 shares for 0.27% of their portfolio. Renaissance Tech Ltd stated it has 977,100 shares. Moreover, Profund Lc has 0.02% invested in Haemonetics Corporation (NYSE:HAE). Moreover, Deutsche Bancorp Ag has 0.01% invested in Haemonetics Corporation (NYSE:HAE) for 300,625 shares. D E Shaw & Incorporated reported 20,508 shares or 0% of all its holdings. 122,859 are owned by Rhumbline Advisers. Parkside National Bank & Trust has 32 shares. Keybank Natl Association Oh holds 0.01% or 37,800 shares. Tiaa Cref Inv Mgmt Ltd invested in 270,197 shares. Moreover, Stifel Fincl has 0% invested in Haemonetics Corporation (NYSE:HAE). Prospector Prns Limited Com reported 0.36% of its portfolio in Haemonetics Corporation (NYSE:HAE).

Since January 2, 2018, it had 0 buys, and 3 selling transactions for $484,765 activity. Shares for $448,434 were sold by KROLL MARK W. Another trade for 389 shares valued at $28,097 was sold by Basil Michelle L.

The stock of Haemonetics Corporation (NYSE:HAE) hit a new 52-week high and has $83.60 target or 9.00 % above today’s $76.70 share price. The 8 months bullish chart indicates low risk for the $4.10B company. The 1-year high was reported on Apr, 23 by Barchart.com. If the $83.60 price target is reached, the company will be worth $368.91M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.81% or $0.62 during the last trading session, reaching $76.7. About 33,702 shares traded. Haemonetics Corporation (NYSE:HAE) has risen 82.56% since April 23, 2017 and is uptrending. It has outperformed by 71.01% the S&P500.

Analysts await Haemonetics Corporation (NYSE:HAE) to report earnings on May, 8 before the open. They expect $0.43 EPS, up 10.26 % or $0.04 from last year’s $0.39 per share. HAE’s profit will be $22.98M for 44.59 P/E if the $0.43 EPS becomes a reality. After $0.62 actual EPS reported by Haemonetics Corporation for the previous quarter, Wall Street now forecasts -30.65 % negative EPS growth.

Haemonetics Corporation (NYSE:HAE) Ratings Coverage

Among 4 analysts covering Haemonetics Corp (NYSE:HAE), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Haemonetics Corp has $80.0 highest and $50.0 lowest target. $69’s average target is -10.04% below currents $76.7 stock price. Haemonetics Corp had 9 analyst reports since November 8, 2017 according to SRatingsIntel. The rating was maintained by Morgan Stanley on Thursday, November 9 with “Equal-Weight”. The rating was maintained by Jefferies on Wednesday, February 7 with “Buy”. The firm has “Buy” rating given on Monday, January 8 by Jefferies. As per Thursday, December 21, the company rating was maintained by Jefferies. The rating was maintained by Craig Hallum with “Hold” on Wednesday, November 8. Morgan Stanley maintained the stock with “Buy” rating in Wednesday, March 28 report. Raymond James upgraded the stock to “Market Perform” rating in Tuesday, January 2 report. The firm earned “Overweight” rating on Tuesday, January 2 by Morgan Stanley. The rating was maintained by Morgan Stanley with “Overweight” on Wednesday, February 7.

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company has market cap of $4.10 billion. The firm operates through five divisions: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It currently has negative earnings. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma clients to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components; and whole blood collection and processing products.

Haemonetics Corporation (NYSE:HAE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.